2024
Radiomics-driven personalized radiotherapy for primary and recurrent tumors: A general review with a focus on reirradiation
Beddok A, Orlhac F, Rozenblum L, Calugaru V, Créhange G, Dercle L, Nioche C, Thariat J, Marin T, El Fakhri G, Buvat I. Radiomics-driven personalized radiotherapy for primary and recurrent tumors: A general review with a focus on reirradiation. Cancer/Radiothérapie 2024, 28: 597-602. PMID: 39406602, DOI: 10.1016/j.canrad.2024.09.002.Peer-Reviewed Original ResearchPersonalized radiotherapyTumor localizationTreatment planningMedian AUCImaging modalitiesRisk of recurrenceHead and neckImprove treatment precisionPredicting clinical outcomesOptimal treatment planQuantitative imaging biomarkersRecurrent tumorsApplication of radiomicsRecurrent cancerClinical radiotherapyExternal validationClinical outcomesRadiotherapyReirradiationLack of external validationMEDLINE searchTreatment precisionImaging biomarkersImaging protocolTumor
2018
[18F]Fluorocholine and [18F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM
Verwer E, Kavanagh T, Mischler W, Feng Y, Takahashi K, Wang S, Shoup T, Neelamegam R, Yang J, Guehl N, Ran C, Massefski W, Cui Y, El-Chemaly S, Sadow P, Oldham W, Kijewski M, Fakhri G, Normandin M, Priolo C. [18F]Fluorocholine and [18F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM. Clinical Cancer Research 2018, 24: 5925-5938. PMID: 30054282, PMCID: PMC6816044, DOI: 10.1158/1078-0432.ccr-17-3693.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnimalsBiomarkersCholineDisease Models, AnimalFemaleFluoroacetatesHeterograftsHumansImage Processing, Computer-AssistedImmunohistochemistryLipid MetabolismLymphangioleiomyomatosisMaleMiceMice, TransgenicMitochondriaOxygen ConsumptionPhosphatidylcholinesPositron-Emission TomographyRatsTuberous SclerosisConceptsTuberous sclerosis complexMetabolic imaging biomarkersPreclinical modelsImaging biomarkersTSC2-deficient cellsStandardized uptake valueTuberous sclerosis complex manifestationsModels of tuberous sclerosis complexAutosomal dominant disorderPotential clinical interestBenign tumorsOvariectomized miceUptake valueSubcutaneous tumorsPreclinical studiesPulmonary nodulesCystic destructionLymphangioleiomyomatosisDominant disorderProliferative lesionsInactivating mutationsTumorMetabolic reprogrammingNeurocognitive impairmentPET imaging